-+ 0.00%
-+ 0.00%
-+ 0.00%

Eton Pharmaceuticals secures US commercialization rights to leishmaniasis drug Impavido

PUBT·05/19/2026 20:30:45
Listen to the news
Eton Pharmaceuticals secures US commercialization rights to leishmaniasis drug Impavido
  • Eton Pharmaceuticals signed a supply and distribution agreement to secure exclusive U.S. commercialization rights to IMPAVIDO (miltefosine) from a Knight Therapeutics affiliate.
  • The exclusive rights take effect Sept. 26, 2026, adding another planned 2026 product launch to Eton’s rare disease portfolio.
  • IMPAVIDO is the only FDA-approved oral therapy for certain forms of leishmaniasis, a rare parasitic disease that can be life-threatening if untreated.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eton Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605191630PRIMZONEFULLFEED9723236) on May 19, 2026, and is solely responsible for the information contained therein.